Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Clinical relevance of the transcriptional signature regulated by CDC42 in colorectal cancer.

Valdés-Mora F, Locke WJ, Bandrés E, Gallego-Ortega D, Cejas P, García-Cabezas MA, Colino-Sanguino Y, Feliú J, Del Pulgar TG, Lacal JC.

Oncotarget. 2017 Apr 18;8(16):26755-26770. doi: 10.18632/oncotarget.15815.

2.

Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer.

Cristóbal I, Manso R, Rincón R, Caramés C, Zazo S, Del Pulgar TG, Cebrián A, Madoz-Gúrpide J, Rojo F, García-Foncillas J.

Br J Cancer. 2014 Aug 12;111(4):756-62. doi: 10.1038/bjc.2014.376. Epub 2014 Jul 8.

3.

Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.

de la Cueva A, Ramírez de Molina A, Alvarez-Ayerza N, Ramos MA, Cebrián A, Del Pulgar TG, Lacal JC.

PLoS One. 2013 Jun 10;8(6):e64961. doi: 10.1371/journal.pone.0064961. Print 2013.

Supplemental Content

Loading ...
Support Center